CIMZIA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug CIMZIA contains one active pharmaceutical ingredient (API):

1	Certolizumab pegol UNII UMD07X179E - CERTOLIZUMAB PEGOL
	Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation constant (KD) of 90 pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. Certolizumab pegol was shown to neutralise membrane associated and soluble human TNFα in a dose-dependent manner. By inhibiting the action of TNFα, certolizumab pegol reduces inflammation and other symptoms in patients with rheumatoid arthritis.
	Read more about Certolizumab pegol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
Cimzia 200 mg solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
CIMZIA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AB05	Certolizumab pegol	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
Discover more medicines within L04AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10137M, 10238W, 10892G, 10896L, 10897M, 10904X, 10905Y, 10909E, 11318Q, 11319R, 11320T, 11321W, 11322X, 11323Y, 11324B, 11325C, 11326D, 12005W, 12013G, 12027B, 12028C, 12040Q, 12063X, 3425G
BR	Câmara de Regulação do Mercado de Medicamentos	525217050021917, 525217050022017
CA	Health Products and Food Branch	02331675, 02465574
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00996241, 01686991, 01751636, 01751978, 06907741, 06907758, 06935186, 07693331, 09245430, 09294291, 10709053, 10709076, 11032322, 11156159, 11514765, 11668132, 12450719, 12450731, 12466293, 12547382, 12547399, 12638044, 13168741, 13425669, 13425675, 13859161, 13859178, 13988964, 14025162, 14025179, 14053230, 14053247, 14055217, 14055223, 14307185, 14367402, 14420119, 14420125, 14445935, 14445964, 16168730, 16168753, 16169089, 16529613, 16808046, 16875628, 16875634
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	H3070113
EE	Ravimiamet	1456107, 1456118, 1699320, 1744556, 1744567, 1744578, 1762916, 1762927, 1762938
ES	Centro de información online de medicamentos de la AEMPS	109544001, 109544005, 109544008
FI	Lääkealan turvallisuus- ja kehittämiskeskus	060812, 066304, 552479
FR	Base de données publique des médicaments	64386835, 66661714
GB	Medicines & Healthcare Products Regulatory Agency	173161, 335119, 378471
HK	Department of Health Drug Office	61805, 67262
IE	Health Products Regulatory Authority	88502, 88677
IL	מִשְׂרַד הַבְּרִיאוּת	7383
JP	医薬品医療機器総合機構	3999437G1022, 3999437G2029
LT	Valstybinė vaistų kontrolės tarnyba	1051600, 1051601, 1072083, 1075875, 1084279, 1084280, 1084281, 1084282, 1084283, 1084284
NL	Z-Index G-Standaard, PRK	137219, 143189, 92584
PL	Rejestru Produktów Leczniczych	100206939
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W54992001, W54992002
TN	Direction de la Pharmacie et du Médicament	3113031H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699624950017
US	FDA, National Drug Code	50474-710